Union Defence Minister Rajnath Singh on Monday will release the first batch of the 2-deoxy-D-glucose (2-DG) drug for the treatment of Covid-19 patients. The drug developed by the Defence Research and Development Organisation (DRDO) in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad. Meanwhile, this drug has proved to be extremely helpful for coronavirus-infected patients with oxygen deficiency. Not only this, it also helps in quick recovery of patients.
Meanwhile, Rajnath Singh's office tweeted, "Raksha Mantri Rajnath Singh will release the first batch of anti-Covid drug 2DG via video conferencing facility tomorrow at 10.30 AM. The drug has been developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories."
On the other hand, DRDO officials further informed that the clinical trial results have shown that this molecule helps hospitalized patients in faster recovery and reduces oxygen dependence. Meanwhile, the patients treated with 2-DG drug have shown RT-PCR negative conversion. In view of ever-increasing cases in India, Drug regulator Indian Drug Controller General DCGI granted the emergency use authorisation to 2-deoxy-D-glucose (2-DG). The DRDO states that the drug can be given to patients with moderate to severe symptoms moderate symptoms.
In Phase-II trials from May to October 2020, the drug found to be safe in patients with COVID-19 symptoms. The Drug showed faster recovery in hospitalised patients. Meanwhile, the Phase-III clinical trial conducted on 220 patients between. December 2020 to March 2021 at 27 COVID hospital in different states. It includes – Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu.